tecfidera 240 mg/1 kapsula gastrorezistentna kapsula, tvrda
medis international d.o.o. sarajevo - dimetil fumarat - gastrorezistentna kapsula, tvrda - 240 mg/1 kapsula - 1 gastrorezistentna kapsula, tvrda sadrži: 240 mg dimetil fumarata
aubagio 14 mg/1 tableta film tableta
sanofi d.o.o. - teriflunomid - film tableta - 14 mg/1 tableta - 1 film tableta sadrži: 14 mg teriflunomida
tysabri 300 mg/15 ml koncentrat za rastvor za infuziju
medis international d.o.o. sarajevo - natalizumab - koncentrat za rastvor za infuziju - 300 mg/15 ml - 1 bočica sa 15 ml koncetrata za rastvor za infuziju sadrži: 300 mg natalizumaba
aubagio 14 mg/1 tableta film tableta
amicus pharma d.o.o. - teriflunomid - film tableta - 14 mg/1 tableta - 1 film tableta sadrži: 14 mg teriflunomida
aubagio 14mg film tableta
dio stranog druŠtva "sanofi - aventis" - podgorica - teriflunomid - film tableta - 14mg
tysabri 150mg rastvor za injekciju u napunjenom injekcionom špricu
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - natalizumab - rastvor za injekciju u napunjenom injekcionom špricu - 150mg
teriflunomid zentiva 14mg film tableta
zentiva pharma doo - dio stranog druŠtva podgorica - teriflunomid - film tableta - 14mg
lemtrada (▼) 12 mg/1 bočica koncentrat za rastvor za infuziju
sanofi d.o.o. - alemtuzumab - koncentrat za rastvor za infuziju - 12 mg/1 bočica - 1 ml koncentrata za rastvor za infuziju sadrži: 10 mg alemtuzumaba
aubagio
sanofi winthrop industrie - teriflunomide - multipla skleroza - selektivni imunosupresivi - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).
teriflunomide mylan
mylan pharmaceuticals limited - teriflunomide - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).